Comparison of different treatment modalities in mild and moderate acne;Ocena różnych metod leczenia tra̧dziku łagodnego i średnio nasilonego

Przeglad Dermatologiczny

Volumn 93, Issue 1, 2006, Pages 47-56

  Kłujszo, Elzbieta ^a   Langner, Andrzej ^b  

^a Wojewódzki Szpital Zespolonego ^*  (Poland)

^b Klinika Dermatologiczna Medical University of Warsaw   (Poland)

Author keywords

Acne vulgaris; Combined therapy; Topical monotherapy

Indexed keywords

ADAPALENE; ANTIBIOTIC AGENT; CLINDACNE; CLINDAMYCIN; ISOTRETINOIN; RETINOID; TAZAROTENE;

ACNE; ADOLESCENT; ADULT; ARTICLE; COMEDO; DESQUAMATION; DOSE TIME EFFECT RELATION; DRUG EFFICACY; ERYTHEMA; HUMAN; MAJOR CLINICAL STUDY; PAPULE; PATHOGENESIS; PRURITUS; PUSTULE; RISK FACTOR; SCHOOL CHILD; STATISTICAL SIGNIFICANCE; XEROSIS;

EID: 33645275185     PISSN: 00332526     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Kraning K.K., Odland G.F.: Prevalence, morbidity and cost of dermatologic diseases. J Invest Dermatol 1979, 73, 395-413.
2. Cunliffe W.J., Gould D.J.: Prevalence of facial acne vulgaris in late adolescence and in adults. BMJ 1979, 11, 9-10.
3. Leyden J.J.: New understandings of the pathogenesis of acne. J Am Acad Dermatol 1995, 32, 15-25.
4. Jappe U.: Pathological mechanisms of acne with special emphasis on Propionibacterium acnes and related therapy. Acta Derm Venereol (Stockh) 2003, 83, 241-248.
5. Gollnick H.: Current concepts of the pathogenesis of acne: implications for drug treatment. Drugs 2003, 63, 1579-1596.
6. Burton J.L., Shuster S.: The relationship between seborrhoea and acne vulgaris. Br J Dermatol 1971, 84, 600-601.
7. Cunliffe W.J., Holland D.B., Clark S.M. i inni: Comedogenesis: some new aetiological, clinical and therapeutic strategies. Br J Dermatol 2000, 142, 1084-1091.
8. Cunliffe W.J., Holland D.B., Jeremy A.: Comedone formation: etiology, clinical presentation, and treatment. Clin Dermatol 2004, 22, 367-374.
9. Ingham E., Eady E.A., Goodwin C.E. i inni: Pro-inflammatory levels of interleukin-1 alpha-like bioactivity are present in the majority of open comedones in acne vulgaris. J Invest Dermatol 1992, 98, 895-901.
10. Zouboulis C.C., Xia L., Akamatsu H. i inni: The human sebocyte culture model provides new insights into development and management of seborrhea and acne. Dermatology 1998, 196, 21-31.
11. Webster G.F.: Inflammation in acne vulgaris. J Am Acad Dermatol 1995, 33, 247-253.
12. Szybejko-Machej G.: Choroby gruczołów potowych i łojowych. [w:] Dermatologia pediatryczna, M. Miklaszewska, F. Wa̧sik (red.), Volumed, Wrocław, 1999, 2, 103-113.
13. O'Brien S.C., Lewis J.B., Cunliffe W.J.: The Leeds revised acne grading system. J Dermatol Treat 1998, 9, 215-220.
14. Gollnick H.P.M., Zouboulis C.C., Akamatsu H. i inni: Pathogenesis and pathogenesis-related treatment of acne. J Dermatol 1991, 18, 489-499.
15. Pawin H., Beylot C., Chivot M. i inni: Physiopathology of acne vulgaris: recent data, new understanding of the treatments. Eur J Dermatol 2004, 14, 4-12.
16. Gollnick H., Schraum M.: Topical drug treatment in acne. Dermatology 1998, 196, 119-125.
17. Leyden J.J.: A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol 2003, 49, 200-210.
18. Weiss J.S., Sharin J.S.: Topical retinoid and antibiotic combination therapy for acne management. J Drugs Dermatol 2004, 3, 146-154.
19. Langner A., Ambroziak M., Bocheński J.: Nowa strategia leczenia tra̧dziku pospolitego. Terapia i leki 2002, 3, 18-21.
20. Eady E.A., Cove J.H., Joanes D.N. i inni: Topical antibiotics for the treatment of a acne vulgaris: a critical evaluation of the literature on their clinical benefit and comparative efficacy. J Dermatol Treat 1990, 1, 215-218.
21. Shalita A.R., Smith E.B., Bauer E.: Topical erythromycin versus clindamycin therapy for acne: a multicenter double-blind comparison. Arch Dermatol 1984, 120, 351-355.
22. Meynadier J., Alirezai M.: Systemic antibiotics for acne. Dermatology 1998, 196, 135-139.
23. Marples R.R., Williamson P.: Effects of systemic demethylchlorotetracycline on human cutaneus microflora. Appl Microbiol 1969, 18, 228-238.
24. Esterly N.B., Furey N.L., Flangan L.E.: The effect of antimicrobical agents on leukocyte chemotaxis. J Invest Dermatol 1978, 70, 51-55.
25. Esterly N.B., Konarsky J.S., Furey N.L. i inni: Neutrophil chemotaxis in patients with acne receiving oral tetracycline therapy. Arch Dermatol 1984, 120, 1308-1313.
26. Unkles S.E., Gemme G.C.: Effect of clindamycin, lincomycin and tetracycline on growth and extracellular lipase production by Propionibacterium in vitro. Antimicrob Agents Chemother 1982, 21, 39-43.
27. Sardana K., Seghal V.N.: Retinoids: fascinating up-and-coming scenario. J Dermatol. 2003, 30, 355-380.
28. Bergfeld W.F.: Topical retinoids in the management of acne vulgaris. J Drug Der Clin Pract 1996, 8, 151-160.
29. Johnson A., Chandraratna R.A.S.: Novel retinoids with receptor selectivity and functional selectivity. Br J Dermatol 1999, 140 (supl. 54), 12-17.
30. Dawson M.I.: Synthetic retinoids and their nuclear receptors. Curr Med Chem Anti-Cane Agents 2004, 4, 199-230.
31. Pietrzykowski A., Nauman A.: Receptory ja̧drowe dla pochodnych witaminy A. Endokrynologia Polska 1996, 47, 293-311.
32. Michel S., Jomard A., Demarchez M.: Pharmacology of adapalene. Br J Dermatol 1998 (supl. 52), 3-7.
33. Zouboulis C.C.: Exploration of retinoid activity and the role of inflammation in acne: issues affecting future directions for acne therapy. J Eur Acad Dermatol Venereol 2001, (supl. 1) 3, 63-67.
34. Hensby C., Cavey D., Boucher M. i inni: The in vivo and in vitro anti-inflammatory activity of CD 271: a new retinoid-like modulator of cell differentiation. Agents Action 1990, 29, 56-58.
35. Thielitz A., Helmach M., Ropke E.M. i inni: Lipid analysis of follicular casts from cyanoacrylate strips as a new method for studying therapeutic effects of antiacne agents. Br J Dermatol 2001, 145, 19-27.
36. Vega B.: Toll-like receptor-2: A novel mechanism of action of Adapalen in the treatment of inflammatory acne lesions. Abstract book EADV 2002 Satellite symposium Optimizing the treatment of inflammatory acne.
37. Kala R.: Elementy wnioskowania parametrycznego dla przyrodników. Wyd. Akademii Rolniczej Poznań 1996.
38. Zoubulis C.C., Derumeaux L., Decroix J. i inni: A multicentre, single-blind randomized comparison of fixed clindamycin phosphate/tretinoin gel formulation (Velac) applied once daily and a clindamycin lotion formulation (DalacinT) applied twice daily in the topical treatment of acne vulgaris. Br J Dermatol 2000, 143, 498-505.
39. Wolf J.E. Jr, Kaplan D., Kraus S.J. i inni: A comparative study on the acne vulgaris with adapalene and clindamycin: a multicenter, randomised, investigator-blinded study. J Am Acad Dermatol 2003, 49, 211-217.
40. Zhang J., Feng L.L., Teng T.Y. i inni: The maintence effect of a treatment with adapalen gel 0.1% in patients with acne vulgaris previously treated with clindamycin topical solution 1% alone or in combination with adapalen gel 0.1%. Am Acad Derm 62 nd Annual Meeting 2004, Feb. 6-11, Washington DC. [poster]
41. Richter J.R., Forstorm L.R., Kiistala U.O. i inni: Efficacy of the fixed 1.2% clindamycin phosphate, 0.025% tretinoin gel formulation (Velac) and a proprietary 0.025% tretinoin gel formulation (Aberela) in the topical control of facial acne. J Eur Acad Dermatol Venereol 1998, 11, 227-233.
42. Rietschel R.L., Duncan S.H.: Clindamycin phosphate used in combination with tretinoin in the treatment of acne. Int J Dermatol 1983, 22, 41-43.
43. Ioannides D., Rigopoulos D., Katsambas A.: Topical adapalen gel 0.1% vs isotretinoin gel 0.05% in the treatment of acne vulgaris: randomized open-label clinical trial. Br J Dermatol 2002, 147, 523-527.
44. Leyden J., Lowe N., Kakita L. i inni: Comparison of treatment of acne vulgaris with alternate -day applications of tazarotene 0.1% gel and once-daily application of adapalene 0.1% gel: a randomized trial. Cutis 2001, 67, 10-16.
45. Webster G., Guenther L., Poulin Y.P. i inni: A multicenter double blind randomized comparison of the efficacy and tolerability of treating facial acne vulgaris once daily with tazarotene 0.1% gel or adapalene 0.1% gel. Cutis 2002, 69, 4-11.